A retrospective study to evaluate Real-world disease burden for patients with myelofibrosis treated with ruxolitinib
Latest Information Update: 12 Jan 2021
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Dec 2020 Results (n=152) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 11 Jun 2020 New trial record
- 31 May 2020 Results (n=104) presented at the 56th Annual Meeting of the American Society of Clinical Oncology